{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:42Z","timestamp":1740108162767,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00066-022-01960-z","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T14:02:45Z","timestamp":1654092165000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-8110","authenticated-orcid":false,"given":"Pierre","family":"Loap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Nicaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Laki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"13","key":"1960_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnci\/dji172","volume":"97","author":"KW Hance","year":"2005","unstructured":"Hance\u00a0KW, Anderson\u00a0WF, Devesa\u00a0SS, Young\u00a0HA, Levine\u00a0PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the national cancer institute. J\u00a0Natl Cancer Inst 97(13):966\u2013975","journal-title":"J Natl Cancer Inst"},{"issue":"5\u20136","key":"1960_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14740\/wjon1161","volume":"9","author":"F Mamouch","year":"2018","unstructured":"Mamouch\u00a0F, Berrada\u00a0N, Aoullay\u00a0Z, El Khanoussi\u00a0B, Errihani\u00a0H (2018) Inflammatory breast cancer: a literature review. World J Oncol 9(5\u20136):129\u2013135","journal-title":"World J Oncol"},{"issue":"2","key":"1960_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2014.09.003","volume":"93","author":"DJP van Uden","year":"2015","unstructured":"van Uden\u00a0DJP, van Laarhoven\u00a0HWM, Westenberg\u00a0AH, de Wilt\u00a0JHW, Blanken-Peeters\u00a0CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol 93(2):116\u2013126","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1960_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3816\/CBC.2004.n.042","volume":"5","author":"E Baldini","year":"2004","unstructured":"Baldini\u00a0E, Gardin\u00a0G, Evagelista\u00a0G, Prochilo\u00a0T, Collecchi\u00a0P, Lionetto\u00a0R (2004) Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 5(5):358\u2013363","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"1960_CR5","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/1097-0142(20011001)92:7<1775::AID-CNCR1693>3.0.CO;2-E","volume":"92","author":"M Cristofanilli","year":"2001","unstructured":"Cristofanilli\u00a0M, Buzdar\u00a0AU, Sneige\u00a0N, Smith\u00a0T, Wasaff\u00a0B, Ibrahim\u00a0N et\u00a0al (2001) Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92(7):1775\u20131782","journal-title":"Cancer"},{"issue":"3","key":"1960_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","volume":"22","author":"S Dawood","year":"2011","unstructured":"Dawood\u00a0S, Merajver\u00a0SD, Viens\u00a0P, Vermeulen\u00a0PB, Swain\u00a0SM, Buchholz\u00a0TA et\u00a0al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515\u2013523","journal-title":"Ann Oncol"},{"issue":"1","key":"1960_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijrobp.2017.01.205","volume":"98","author":"N Grellier Adedjouma","year":"2017","unstructured":"Grellier Adedjouma\u00a0N, Chevrier\u00a0M, Fourquet\u00a0A, Costa\u00a0E, Xu\u00a0H, Berger\u00a0F et al (2017) Long-term results of a\u00a0highly performing conformal electron therapy technique for chest wall irradiation after mastectomy. Int J Radiat Oncol Biol Phys 98(1):206\u2013214","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"1960_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ijrobp.2007.05.007","volume":"69","author":"YM Kirova","year":"2007","unstructured":"Kirova\u00a0YM, Campana\u00a0F, Fournier-Bidoz\u00a0N, Stilhart\u00a0A, Dendale\u00a0R, Bollet\u00a0MA et al (2007) Postmastectomy electron beam chest wall irradiation in women with breast cancer: a\u00a0clinical step toward conformal electron therapy. Int J Radiat Oncol Biol Phys 69(4):1139\u20131144","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1960_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.radonc.2021.09.012","volume":"164","author":"O Kaidar-Person","year":"2021","unstructured":"Kaidar-Person\u00a0O, Dahn\u00a0HM, Nichol\u00a0AM, Boersma\u00a0LJ, de Ruysscher\u00a0D, Meattini\u00a0I et al (2021) A Delphi study and international consensus recommendations: the use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiother Oncol 164:115\u2013121","journal-title":"Radiother Oncol"},{"issue":"3","key":"1960_CR10","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/j.clon.2022.01.007","volume":"34","author":"P Loap","year":"2022","unstructured":"Loap\u00a0P, Nicaise\u00a0B, Laki\u00a0F, Loirat\u00a0D, Pierga\u00a0JY, Fourquet\u00a0A et al (2022) A therapeutic challenge: chemo-refractory non-metastatic inflammatory breast cancers. Clin Oncol (R Coll Radiol) 34(3):e140","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1960_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/IJWH.S178349","volume":"11","author":"J Mehanna","year":"2019","unstructured":"Mehanna\u00a0J, Haddad\u00a0FG, Eid\u00a0R, Lambertini\u00a0M, Kourie\u00a0HR (2019) Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health 11:431\u2013437","journal-title":"Int J Womens Health"},{"issue":"22","key":"1960_CR12","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin\u00a0NU, Vanderplas\u00a0A, Hughes\u00a0ME, Theriault\u00a0RL, Edge\u00a0SB, Wong\u00a0YN et al (2012) Clinicopathological features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer 118(22):5463\u20135472","journal-title":"Cancer"},{"issue":"9938","key":"1960_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar\u00a0P, Zhang\u00a0L, Untch\u00a0M, Mehta\u00a0K, Costantino\u00a0JP, Wolmark\u00a0N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172","journal-title":"Lancet"},{"issue":"3","key":"1960_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1245\/s10434-015-4921-5","volume":"23","author":"SK Swisher","year":"2016","unstructured":"Swisher\u00a0SK, Vila\u00a0J, Tucker\u00a0SL, Bedrosian\u00a0I, Shaitelman\u00a0SF, Litton\u00a0JK et al (2016) Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol 23(3):749\u2013756","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1960_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.radonc.2011.08.017","volume":"102","author":"MA Bollet","year":"2012","unstructured":"Bollet\u00a0MA, Belin\u00a0L, Reyal\u00a0F, Campana\u00a0F, Dendale\u00a0R, Kirova\u00a0YM et al (2012) Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a\u00a0phase II trial. Radiother Oncol 102(1):82\u201388","journal-title":"Radiother Oncol"},{"issue":"17","key":"1960_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/jnci\/88.17.1193","volume":"88","author":"CJ McGinn","year":"1996","unstructured":"McGinn\u00a0CJ, Shewach\u00a0DS, Lawrence\u00a0TS (1996) Radiosensitizing nucleosides. J\u00a0Natl Cancer Inst 88(17):1193\u20131203","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1960_CR17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.21.02054","volume":"40","author":"H Joensuu","year":"2022","unstructured":"Joensuu\u00a0H, Kellokumpu-Lehtinen\u00a0PL, Huovinen\u00a0R, Jukkola\u00a0A, Tanner\u00a0M, Ahlgren\u00a0J et al (2022) Adjuvant capecitabine for early breast cancer: 15-year overall survival results from a randomized trial. J\u00a0Clin Oncol 40(10):1051\u20131058","journal-title":"J Clin Oncol"},{"issue":"22","key":"1960_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda\u00a0N, Lee\u00a0SJ, Ohtani\u00a0S, Im\u00a0YH, Lee\u00a0ES, Yokota\u00a0I et\u00a0al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N\u00a0Engl J Med 376(22):2147\u20132159","journal-title":"N Engl J Med"},{"issue":"4","key":"1960_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","volume":"99","author":"WA Woodward","year":"2017","unstructured":"Woodward\u00a0WA, Fang\u00a0P, Arriaga\u00a0L, Gao\u00a0H, Cohen\u00a0EN, Reuben\u00a0JM et\u00a0al (2017) A phase 2\u00a0study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys 99(4):777\u2013783","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1960_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clbc.2020.02.010","volume":"20","author":"AD Sherry","year":"2020","unstructured":"Sherry\u00a0AD, Mayer\u00a0IA, Ayala-Peacock\u00a0DN, Abramson\u00a0VG, Rexer\u00a0BN, Chakravarthy\u00a0AB (2020) Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity. Clin Breast Cancer 20(4):344\u2013352.e1","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1960_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0169-5002(01)00265-3","volume":"34","author":"K Fukuoka","year":"2001","unstructured":"Fukuoka\u00a0K, Arioka\u00a0H, Iwamoto\u00a0Y, Fukumoto\u00a0H, Kurokawa\u00a0H, Ishida\u00a0T et al (2001) Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34(3):451\u2013460","journal-title":"Lung Cancer"},{"issue":"2","key":"1960_CR22","first-page":"41","volume":"23","author":"MP Edelstein","year":"1996","unstructured":"Edelstein\u00a0MP, Wolfe\u00a0LA, Duch\u00a0DS (1996) Potentiation of radiation therapy by vinorelbine (navelbine) in non-small cell lung cancer. Semin Oncol 23(2):41\u201347","journal-title":"Semin Oncol"},{"issue":"6","key":"1960_CR23","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.1998.16.6.2157","volume":"16","author":"GA Masters","year":"1998","unstructured":"Masters\u00a0GA, Haraf\u00a0DJ, Hoffman\u00a0PC, Drinkard\u00a0LC, Krauss\u00a0SA, Ferguson\u00a0MK et\u00a0al (1998) Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J\u00a0Clin Oncol 16(6):2157\u20132163","journal-title":"J Clin Oncol"},{"issue":"1","key":"1960_CR24","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","volume":"11","author":"N Chopra","year":"2020","unstructured":"Chopra\u00a0N, Tovey\u00a0H, Pearson\u00a0A, Cutts\u00a0R, Toms\u00a0C, Proszek\u00a0P et\u00a0al (2020) Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun 11(1):2662","journal-title":"Nat Commun"},{"issue":"7","key":"1960_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/1940-6207.CAPR-14-0047","volume":"7","author":"C To","year":"2014","unstructured":"To\u00a0C, Kim\u00a0EH, Royce\u00a0DB, Williams\u00a0CR, Collins\u00a0RM, Risingsong\u00a0R et al (2014) The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 7(7):698\u2013707","journal-title":"Cancer Prev Res (Phila)"},{"issue":"13","key":"1960_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","volume":"36","author":"R Jagsi","year":"2018","unstructured":"Jagsi\u00a0R, Griffith\u00a0KA, Bellon\u00a0JR, Woodward\u00a0WA, Horton\u00a0JK, Ho\u00a0A et\u00a0al (2018) Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase I multicenter study. J\u00a0Clin Oncol 36(13):1317\u20131322","journal-title":"J Clin Oncol"},{"issue":"2","key":"1960_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijrobp.2020.09.032","volume":"109","author":"P Loap","year":"2021","unstructured":"Loap\u00a0P, Loirat\u00a0D, Berger\u00a0F, Ricci\u00a0F, Vincent-Salomon\u00a0A, Ezzili\u00a0C et al (2021) Combination of olaparib and radiation therapy for triple negative breast cancer: preliminary results of the RADIOPARP phase 1 trial. Int J Radiat Oncol Biol Phys 109(2):436\u2013440","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1960_CR28","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/ijc.33737","volume":"149","author":"P Loap","year":"2021","unstructured":"Loap\u00a0P, Loirat\u00a0D, Berger\u00a0F, Cao\u00a0K, Ricci\u00a0F, Jochem\u00a0A et al (2021) Combination of olaparib with radiotherapy for triple-negative breast cancers: one-year toxicity report of the RADIOPARP phase I trial. Int J Cancer 149(10):1828\u20131832","journal-title":"Int J Cancer"},{"issue":"25","key":"1960_CR29","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt\u00a0ANJ, Garber\u00a0JE, Kaufman\u00a0B, Viale\u00a0G, Fumagalli\u00a0D, Rastogi\u00a0P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N\u00a0Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"6","key":"1960_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson\u00a0M, Im\u00a0SA, Senkus\u00a0E, Xu\u00a0B, Domchek\u00a0SM, Masuda\u00a0N et\u00a0al (2017) Olaparib for metastatic breast cancer in patients with a\u00a0germline BRCA mutation. N\u00a0Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"issue":"9","key":"1960_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid\u00a0P, Cortes\u00a0J, Pusztai\u00a0L, McArthur\u00a0H, K\u00fcmmel\u00a0S, Bergh\u00a0J et al (2020) Pembrolizumab for early triple-negative breast cancer. N\u00a0Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"19","key":"1960_CR32","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.3390\/cancers13194790","volume":"13","author":"A Aboudaram","year":"2021","unstructured":"Aboudaram\u00a0A, Loap\u00a0P, Loirat\u00a0D, Dhia\u00a0SB, Cao\u00a0K, Fourquet\u00a0A et\u00a0al (2021) Pertuzumab and trastuzumab combination with concomitant locoregional radiotherapy for the treatment of breast cancers with HER2 receptor overexpression. Cancers (Basel) 13(19):4790","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1960_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","volume":"10","author":"B Kaufman","year":"2009","unstructured":"Kaufman\u00a0B, Trudeau\u00a0M, Awada\u00a0A, Blackwell\u00a0K, Bachelot\u00a0T, Salazar\u00a0V et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a\u00a0phase II study. Lancet Oncol 10(6):581\u2013588","journal-title":"Lancet Oncol"},{"issue":"2","key":"1960_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-017-2548-z","volume":"134","author":"C Christodoulou","year":"2017","unstructured":"Christodoulou\u00a0C, Kalogera-Fountzila\u00a0A, Karavasilis\u00a0V, Kouvatseas\u00a0G, Papandreou\u00a0CN, Samantas\u00a0E et al (2017) Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a\u00a0phase II study of the hellenic cooperative oncology group (heCOG). J\u00a0Neurooncol 134(2):443\u2013451","journal-title":"J Neurooncol"},{"issue":"2","key":"1960_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ijrobp.2008.01.039","volume":"72","author":"IJ Bristol","year":"2008","unstructured":"Bristol\u00a0IJ, Woodward\u00a0WA, Strom\u00a0EA, Cristofanilli\u00a0M, Domain\u00a0D, Singletary\u00a0SE et\u00a0al (2008) Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 72(2):474\u2013484","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1960_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.prro.2019.05.011","volume":"9","author":"SR Stecklein","year":"2019","unstructured":"Stecklein\u00a0SR, Rosso\u00a0KJ, Nuanjing\u00a0J, Tadros\u00a0AB, Weiss\u00a0A, DeSnyder\u00a0SM et\u00a0al (2019) Excellent locoregional control in inflammatory breast cancer with a\u00a0personalized radiation therapy approach. Pract Radiat Oncol 9(6):402\u2013409","journal-title":"Pract Radiat Oncol"},{"key":"1960_CR37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4028\/www.scientific.net\/AMR.1084.406","volume":"1084","author":"Z Startseva","year":"2015","unstructured":"Startseva\u00a0Z, Musabaeva\u00a0L, Lisin\u00a0V (2015) Multimodality treatment of locally-advanced breast cancer using 6.3\u202fmeV fast neutrons and quality of life in patients in long-term follow-up. AMR 1084:406\u2013408","journal-title":"AMR"},{"issue":"1","key":"1960_CR38","doi-asserted-by":"publisher","first-page":"020069","DOI":"10.1063\/1.4960288","volume":"1760","author":"VV Velikaya","year":"2016","unstructured":"Velikaya\u00a0VV, Musabaeva\u00a0LI, Lisin\u00a0VA, Startseva\u00a0ZA (2016) 6.3\u202fMeV fast neutrons in the treatment of patients with locally advanced and locally recurrent breast cancer. AIP Conf Proc 1760(1):20069","journal-title":"AIP Conf Proc"},{"issue":"2","key":"1960_CR39","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1016\/j.ijrobp.2017.06.641","volume":"99","author":"K Karasawa","year":"2017","unstructured":"Karasawa\u00a0K, Omatsu\u00a0T, Fukuda\u00a0S, Okonogi\u00a0N, Kamada\u00a0T (2017) Four-year experience and future plan of carbon-Ion radiation therapy for breast cancer. Int J Radiat Oncol Biol Physics 99(2):E21","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"1960_CR40","unstructured":"Fujimoto T, Maekawa Y, Takao S, Hori S, Andoh T, Sakurai Y, Tanaka H, Kinashi Y, Masunaga S, Ichikawa H et al (2016) Anti-tumor effect of boron neutron capture therapy (BNCT) on axillary lymph node metastasis of breast cancer. KURRI Prog Rep 44"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01960-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-01960-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01960-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T16:18:42Z","timestamp":1673626722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-01960-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1960"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-01960-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Loap, B.\u00a0Nicaise, F.\u00a0Laki, D.\u00a0Loirat, J.-Y.\u00a0Pierga, A.\u00a0Fourquet, and Y.\u00a0Kirova declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}